Neoadjuvant Immunotherapy Strategies in HPV-Related Head-and-Neck Cancer.

ABSTRACT:

Purpose of review

Herein, we review current evidence and future directions of neoadjuvant immunotherapy in HPV-related head and neck squamous cell carcinoma (HNSCC) by describing published data and ongoing clinical trials.

Recent findings

Although HNSCCs have shown response to immune checkpoint inhibitors in recurrent/metastatic disease, a limited number of patients benefit from this treatment. There is an expanding interest in clarifying the clinical benefit of immunotherapy in earlier stage disease setting including at initial presentation. Neoadjuvant immunotherapy for HPV-related HNSCCs represents a rational approach, as these cancers bear strong viral antigens.

Summary

The majority of patients with HPV-related HNSCC have good prognosis and treatment de-intensific

SUBMITTER: Saito S 

PROVIDER: S-EPMC9385129 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature